Evidence map›Paper›PMID 32440769›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Pyrrolidine dithiocarbamate reduces alloxan-induced kidney damage by decreasing nox4, inducible nitric oxide synthase, and metalloproteinase-2.

Bruna Pinheiro Pereira, Gabriel Tavares do Valle, Bruno César Côrrea Salles, Karla Cristinne Mancini Costa, Marilene Lopes Ângelo, Larissa Helena Lobo Torres, Rômulo Dias Novaes, Sílvia Graciela Ruginsk, Carlos Renato Tirapelli, Fernanda Borges de Araújo Paula and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bruna Pinheiro PereiraDepartamento de Alimentos e Medicamentos, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais,, Brazil.
Gabriel Tavares do ValleEscola de Enfermagem de Ribeirão Preto (EERP), Universidade de São Paulo - USP, Sao Paulo, Brazil.
Bruno César Côrrea SallesDepartamento de Análises Clínicas, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil.
Karla Cristinne Mancini CostaDepartamento de Alimentos e Medicamentos, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais,, Brazil.
Marilene Lopes ÂngeloDepartamento de Alimentos e Medicamentos, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais,, Brazil.
Larissa Helena Lobo TorresDepartamento de Alimentos e Medicamentos, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais,, Brazil.
Rômulo Dias NovaesDepartamento de Biologia Estrutural, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil.
Sílvia Graciela RuginskDepartamento de Ciências Fisiológicas, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil.
Carlos Renato TirapelliEscola de Enfermagem de Ribeirão Preto (EERP), Universidade de São Paulo - USP, Sao Paulo, Brazil.
Fernanda Borges de Araújo PaulaDepartamento de Análises Clínicas, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais, Brazil.
Carla Speroni CeronDepartamento de Alimentos e Medicamentos, Universidade Federal de Alfenas (UNIFAL-MG), Alfenas, Minas Gerais,, Brazil. carlasceron@gmail.com.ORCID http://orcid.org/0000-0001-8882-5792
Universidade Federal de Alfenas · BRUniversidade de Ribeirão Preto · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 406177/2016-3Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01239-16 and PPM-00383-18Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/22046-8
6 · The paper itself

Abstract

We examined the effect of the NFκB inhibitor pyrrolidine-1-carbodithioic acid (PDTC) on inducible nitric oxide synthase (iNOS), matrix metalloproteinase-2 (MMP-2) activity, and oxidative and inflammatory kidney damage in alloxan-induced diabetes. Two weeks after diabetes induction (alloxan-130 mg/kg), control and diabetic rats received PDTC (100 mg/kg) or vehicle for 8 weeks. Body weight, glycemia, urea, and creatinine were measured. Kidney changes were measured in hematoxylin/eosin sections and ED1 by immunohistochemistry. Kidney thiobarbituric acid reactive substances (TBARS), superoxide anion (O2-), and nitrate/nitrite (NOx) levels, and catalase and superoxide dismutase (SOD) activities were analyzed. Also, kidney nox4 and iNOS expression, and NFkB nuclear translocation were measured by western blot, and MMP-2 by zymography. Glycemia and urea increased in alloxan rats, which were not modified by PDTC treatment. However, PDTC attenuated kidney structural alterations and macrophage infiltration in diabetic rats. While diabetes increased both TBARS and O

Indexed as

Matrix Metalloproteinase 2AlloxanAnimalsAntioxidantsKidney DiseasesMaleMatrix Metalloproteinase InhibitorsNADPH Oxidase 4Nitric Oxide Synthase Type IIPyrrolidinesRatsRats, WistarThiocarbamatesAlloxanAntioxidantsMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsMmp2 protein, ratNADPH Oxidase 4Nitric Oxide Synthase Type IINos2 protein, ratNox4 protein, ratpyrrolidine dithiocarbamic acidPyrrolidinesThiocarbamatesAlloxan-induced diabetesInducible nitric oxide synthaseKidney damageMatrix metalloproteinasesOxidative stressPyrrolidine dithiocarbamate

Identifiers

PMID32440769
OpenAlexW3027748978

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.